Gan & Lee(603087) 西南证券·2024-10-31 06:05Investment Rating - The report maintains a "Hold" rating for the company [2] Core Insights - The company reported a revenue of 2.25 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 17.8%, and a net profit attributable to shareholders of 510 million yuan, up 90.4% year-on-year [2] - The third quarter performance met expectations, with quarterly revenues of 560 million, 750 million, and 930 million yuan for Q1, Q2, and Q3 respectively, showing year-on-year growth of 0.4%, 12.3%, and 37.6% [3] - The gross margin for the first three quarters was 75.4%, an increase of 0.6 percentage points year-on-year, primarily driven by price adjustments following the continuation of centralized procurement [3] - The company has made significant progress in its key drug pipelines, with promising clinical data for its GLP-1Ra drug GZR-18 and fourth-generation insulin GZR4 [4] - Earnings per share (EPS) forecasts for 2024-2026 are projected at 1.11 yuan, 1.84 yuan, and 2.36 yuan respectively, reflecting strong growth potential from domestic and international markets [4] Financial Summary - For 2023, the company achieved a revenue of 2.608 billion yuan, with a projected revenue of 3.415 billion yuan for 2024, indicating a growth rate of 30.95% [8] - The net profit attributable to shareholders for 2023 was 340.07 million yuan, with projections of 667.39 million yuan for 2024, representing a growth rate of 96.25% [8] - The gross margin is expected to remain strong, with forecasts of 75.62% for 2024 and 73.80% for 2025 [8]